Profile and Antithrombotic Management of Patients With NVAF Attending Internal Medicine Departments in Spain (PERFILAR Study)

Bristol-Myers Squibb (BMS) logo

Bristol-Myers Squibb (BMS)




Anticoagulation, Blood Thinners , Atrial Fibrillation, Bleeding, Stroke

Study type


Funder types




Details and patient eligibility


This is a national, multicenter, cross-sectional, observational study within a convenience sample of Internal Medicine departments from 100 hospitals in Spain which agree to participate in the study. This study will be a cross-sectional chart review which will require the collection of data from medical records and from face-to-face interviews conducted during the inclusion visit. Physician interviews are needed to collect three variables of interest, recommended by the Spanish Society of Internal Medicine as necessary data about profile and management of NVAF patients: cognitive deterioration based on the patient's responses, physician's assessment of the patient's life expectancy, and physician's opinion of the antithrombotic treatment previously prescribed. The investigators will only provide their opinion on previously prescribed therapies (i.e. prescribed before F2F). Hospitals to be contacted for the study include those known to participate in observational studies in Spain; the hospitals will therefore not be a random sample of Spanish hospitals.


987 patients




18+ years old


No Healthy Volunteers

Inclusion and exclusion criteria

For more information regarding BMS clinical trial participation, please visit

Inclusion Criteria:

  • Adult patients (≥18 years old)
  • Patients diagnosed with Non-valvular atrial fibrillation (NVAF) any time prior to the inclusion date (prevalent or incident patients)
  • Patients treated or not treated with an antithrombotic therapy
  • Treated patients should have begun treatment prior to the inclusion visit
  • Patients attending Internal Medicine departments, either for a hospital appointment (outpatients) or hospitalization (inpatients) for any reason)
  • Patients which signed the informed consent

Exclusion Criteria:

  • Patients diagnosed with valvular atrial fibrillation any time in their medical records
  • Patients with anticoagulant treatment prescribed for venous thromboembolic disease any time prior to the inclusion date
  • Patients which participated in any clinical trial with anticoagulant and/or antiplatelet agents in the previous six months
  • Patients incapable of giving their informed consent

Trial design

987 participants in 2 patient groups

In patients
Out patients

Trial contacts and locations



Data sourced from

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems